Advertisement · 728 × 90

Posts by

Preview
South Sudan: MSF strongly condemns the bombing of its hospital in Old Fangak, Jonglei State | Doctors Without Borders / Médecins Sans Frontières (MSF ... Doctors Without Borders/Médecins Sans Frontières (MSF) strongly condemns the bombing of its hospital in Old Fangak, South Sudan. The attack began at around 4:30am when two helicopter gunships first dr...

#SouthSudan: MSF strongly condemns the bombing of its hospital in Old Fangak, Jonglei State.

Bombing of only hospital in Old Fangak puts healthcare of 110,000 people at risk.

www.doctorswithoutborders.ca/south-sudan-...

11 months ago 202 102 4 4

5/
Today, improved treatments and more effective medical tools are available for tackling this deadly infectious disease. What we need now is bold, collective action to deliver them—at scale and with urgency. #EndTB #MDRTB

11 months ago 1 1 0 0

4/
Despite strong health systems , over 65,000 new cases of MDR/RR-TB were reported in the European region in 2023. This is a wake-up call. We can't let outdated approaches hold back progress when better, faster, people-centered treatments and practices are within reach. @unitaid.bsky.social

11 months ago 1 1 1 0

3/
This workshop was a much-needed space to:
🔸 Share experiences & good practices
🔸 Celebrate wins
🔸 Tackle persistent challenges
🔸 Strategize for realistic adoption & scale-up of new TB treatments
🔸Ensure collaboration across the European region
@who.int

11 months ago 1 0 1 0

@MSF has been working hand-in-hand with national TB programmes in several countries across the region—introducing shorter, more effective treatment regimens and person-centered care models. The goal - Improved adherence and increased TB treatment success rates. @kncvtbplus.bsky.social

11 months ago 1 1 1 0
Post image

1/
Glad to have been part of an invigorating 3-day workshop to accelerate the uptake of new WHO TB policies across the WHO European region. Experts from 12 countries joined in—national TB programmes, labs, implementers, donors, civil society & technical partners. @msf.ca 🧵

11 months ago 1 1 1 0
Preview
Cost analysis of the TB-PRACTECAL clinical trial on novel tuberculosis treatment regimens Clinical trials are considered to be the largest contributor to pharmaceutical development costs. However, public disclosure of the costs of individual clinical trials is rare. Médecins Sans Frontiè...

Just out! journals.plos.org/globalpublic... Clinical trial costs transparency as a tool to facilitate equitable access. A call to action! Please spread the word @msf.ca @madhupai.bsky.social @johngreensbluesky.bsky.social @catherineberry.bsky.social @sgschumacher.bsky.social @cdmitpih.bsky.social

11 months ago 3 1 0 1
Post image

Wonderful to see these excellent results from a large, multi-country evaluation of tongue swabs for TB diagnosis!

Diagnostic accuracy of swab-based molecular tests for tuberculosis using novel near point-of-care platforms: A multi-country evaluation

www.medrxiv.org/content/10.1...

1 year ago 28 13 1 1
Advertisement
YOUNITE TB Song - World TB Day 2025
YOUNITE TB Song - World TB Day 2025 YouTube video by YOUNITE GLOBAL

If you haven't seen this music video from team @younite4tb.bsky.social yet - you must check it out NOW to stay inspired in dark times to keep up the fight. Together - #YesWeCanEndTB
#CommitInvestDeliver #EndTB

youtu.be/uoPfKzs9NhU?...

11 months ago 4 3 0 1
Video

#Nigeria: Hear from our colleague, Mercy Jonah Ejura, Nursing Team Supervisor, as she discusses the Sokoto vaccination campaign and the progress being made in protecting children from diseases like measles and diphtheria.

ow.ly/YBUR50V5GOq

1 year ago 157 28 0 0
Preview
The Effectiveness and Safety of Bedaquiline, Pretomanid, and Linezolid (BPaL)–Based Regimens for Rifampicin-Resistant Tuberculosis in Non-Trial Settings—A Prospective Cohort Study in Belarus and Uzbek... Treatment for multidrug-resistant/rifampicin-resistant tuberculosis (TB) and pre–extensively drug-resistant TB using 24-week all-oral bedaquiline, pretoman

Excellent work by @msf.ca @msfsci.bsky.social, @who.int, Uzbekistan and Belarusian colleagues on real world evidence for #BPaLM and #BPaLC 6 months treatment for rifampicin-resistant #TB @lshtmamrcentre.bsky.social @ucltb.bsky.social

1 year ago 1 1 0 0

#AidJobs: We are hiring, here is your chance to work with us.

International Secretary General: bit.ly/42VhaWN

Deputy Logistics Coordinator: bit.ly/4gIVDUf

Tembo Support Officer: bit.ly/4gJ9WIK

5 Nutritionists- bit.ly/3CVtzPW

Finance and Human Resources Manager: bit.ly/3QjZLzo

1 year ago 944 407 13 10
Access bedaquiline | StopTB Partnership

A bright light in a dark moment: The price of the critical TB drug bedaquiline has now dropped to $90 per adult treatment course for TB, a 54% reduction since just 2023.

This is a huge win for @tbfighters.org and the TB activism community generally. www.stoptb.org/what-we-do/f... (1/2)...

1 year ago 8940 994 138 38
Preview
24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation This trial-based evidence adds to consistent indications from modelling studies that BPaL-based regimens are cost-saving for both the patient and health system. Urgent implementation of BPaL-based reg...

24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation - The Lancet Global Health www.thelancet.com/journals/lan... #BPaLM for #TB more evidence. @catherineberry.bsky.social @lshtm.bsky.social

1 year ago 0 1 0 0
Post image Post image Post image Post image

🆕🔥Just published 🔥🆕
Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis(TB)
An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline #idsky #TBsky
www.atsjournals.org/doi/full/10....

1 year ago 37 19 1 3
Post image

Today WHO released Guidance on evidence generation (GEG) on new regimens for #TB treatment — a first-of-its-kind document that advises researchers, developers, funders, and other stakeholders about how evidence should be generated to optimally inform WHO guideline development.

1 year ago 17 6 1 1
https://buff.ly/3Bx6MJl

t.co/KKIjK9ss73?s...
@who.int publishes Guidance on evidence generation (GEG) on new regimens for #TB treatment guidance. @msfsci.bsky.social

1 year ago 1 0 0 0
Advertisement

We are happy to be top of mind this year on @theguardian.com for their yearly donor appeal.

Our work in crises around the world is only possible due to our independent funding. It’s what allows us to deliver neutral and impartial humanitarian medical care where it’s needed most.

1 year ago 154 45 0 0
Preview
The Broken Lens: Antimicrobial Resistance in Humanitarian Settings MSF report on treating AMR in people caught in challenging humanitarian settings

Our recent report on #AntimicrobialResistance & the need for improved surveillance, testing, infection control, #antibiotic stewardship, funding & global commitments for #AMR solutions in humanitarian settings. #WAAW2024 #MedSky

msfaccess.org/broken-lens-...

1 year ago 10194 762 76 20